Last reviewed · How we verify
NCT04392700
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
Phase 3 trial testing Tenofovir disoproxil fumarate 300mg in Hepatocellular Carcinoma Recurrent in 706 participants. Status unknown.
25 July 2021
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 706 |
| Start date | 25 July 2019 |
| Primary completion | 25 July 2021 |
| Estimated completion | 25 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tenofovir disoproxil fumarate 300mg — full drug profile →
- Entecavir 0.5 mg — full drug profile →
Conditions studied
- Hepatocellular Carcinoma Recurrent — all drugs for Hepatocellular Carcinoma Recurrent →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 80, any sex, with Hepatocellular Carcinoma Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis B-related hepatocellular carcinoma after curative resection in adults. Half of participants will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04392700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tenofovir disoproxil fumarate 300mg
Trials testing the same drug.
- NCT05286346 — Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumara · Phase 4 · completed
- NCT03566030 — Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resi · unknown
- NCT05282407 — A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoprox · Phase 4 · completed
- NCT03468907 — The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation · Phase 4 · completed
Other recruiting trials for Hepatocellular Carcinoma Recurrent
Currently open trials in the same condition.
- NCT06254248 — Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04392700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 19 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04392700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing